IDEXX Laboratories (NASDAQ:IDXX) shares surged 5.64% in pre-market trading on Monday after the company reported better-than-expected third-quarter results and raised its full-year guidance. The veterinary diagnostics company's strong performance demonstrates the resilience of its business model and the growing demand for animal health services.

For the third quarter, IDEXX reported earnings per share of $3.22, surpassing the analyst consensus estimate of $3.13 by 2.84%. This represents a significant 15.41% increase from the $2.79 per share reported in the same period last year. The company's quarterly revenue also impressed, coming in at $1.105 billion, beating the analyst estimate of $1.073 billion by 3.01% and marking a 13.27% year-over-year increase.

In light of the strong results, IDEXX has raised its full-year 2025 guidance. The company now expects earnings per share to be in the range of $12.81 to $13.01, up from the previous guidance of $12.40 to $12.76. Revenue projections for the year have also been increased to between $4.27 billion and $4.30 billion, compared to the earlier forecast of $4.21 billion to $4.28 billion. This optimistic outlook has further fueled investor enthusiasm, contributing to the stock's pre-market rally.